Nomenclature
EC number
3.4.22.69
Recommended name
SARS coronavirus main proteinase
Synonyms
3C-like protease <2,3> [9,16,38,49,51]
3CL protease <2> [14,48]
3cLpro <1,2,3> [7,11,13,16,19,28,38,49,51]
C30.004 (Merops-ID)
Mpro
SARS 3C-like protease <2> [17]
SARS 3C-like proteinase <2> [15,18,27]
SARS 3CL protease <2> [31]
SARS 3CLpro <2> [49]
SARS CoV main proteinase <2> [1,2,4,5]
SARS CoVMpro <2> [33]
SARS Mpro <2> [25]
SARS coronavirus 3C-like protease <2> [48]
SARS coronavirus 3C-like proteinase <2> [50]
SARS coronavirus 3CL protease <2> [20]
SARS coronavirus main peptidase <2> [23]
SARS coronavirus main protease <2> [25]
SARS coronavirus main proteinase <2> [5,33]
SARS main protease <2> [12,25]
SARS-3CL protease <2> [48]
SARS-3CLpro <2> [29,50]
SARS-CoV 3C-like peptidaseSARS-CoV 3C-like peptidase<2> [24]
SARS-CoV 3C-like protease<1> [19]
SARS-CoV 3CL protease <2> [22,30,44,46]
SARS-CoV 3CLpro <2> [32,36,38,44,45]
SARS-CoV 3CLpro enzyme <2> [11]
SARS-CoV Mpro <2> [21,40]
SARS-CoV main protease <2> [21,26,43]
SARS-coronavirus 3CL protease <2> [8]
SARS-coronavirus main protease <2> [47]
TGEV Mpro
coronavirus 3C-like protease <1> [19]
porcine transmissible gastroenteritis virus Mpro
severe acute respiratory syndrome coronavirus 3C-like protease <2> [41,42]
severe acute respiratory syndrome coronavirus main protease <2> [21]
severe acute respiratory syndrome coronavirus main proteinase <2> [33]
CAS registry number
218925-73-6
37353-41-6
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Xu, T.; Ooi, A.; Lee, H.C.; Wilmouth, R.; Liu, D.X.; Lescar, J.: Structure of the SARS coronavirus main proteinase as an active C2 crystallographic dimer. Acta Crystallogr. Sect. F, 61, 964-966 (2005)
Zhang, X.W.; Yap, Y.L.: Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg. Med. Chem., 12, 2517-2521 (2004)
Graziano, V.; McGrath, W.J.; DeGruccio, A.M.; Dunn, J.J.; Mangel, W.F.: Enzymatic activity of the SARS coronavirus main proteinase dimer. FEBS Lett., 580, 2577-2583 (2006)
Tan, J.; Verschueren, K.H.; Anand, K.; Shen, J.; Yang, M.; Xu, Y.; Rao, Z.; Bigalke, J.; Heisen, B.; Mesters, J.R.; Chen, K.; Shen, X.; Jiang, H.; Hilgenfeld, R.: pH-dependent conformational flexibility of the SARS-CoV main proteinase (M(pro)) dimer: molecular dynamics simulations and multiple X-ray structure analyses. J. Mol. Biol., 354, 25-40 (2005)
Graziano, V.; McGrath, W.J.; Yang, L.; Mangel, W.F.: SARS CoV main proteinase: The monomer-dimer equilibrium dissociation constant. Biochemistry, 45, 14632-14641 (2006)
Goetz, D.H.; Choe, Y.; Hansell, E.; Chen, Y.T.; McDowell, M.; Jonsson, C.B.; Roush, B.C.; McKerrow, J.; Craik, C.S.: Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. Biochemistry, 46, 8744-8752 (2007)
Solowiej, J.; Thomson, J.A.; Ryan, K.; Luo, C.; He, M.; Lou, J.; Murray, B.W.: Steady-state and pre-steady-state kinetic evaluation of severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro cysteine protease: development of an ion-pair model for catalysis. Biochemistry, 47, 2617-2630 (2008)
Hamill, P.; Hudson, D.; Kao, R.Y.; Chow, P.; Raj, M.; Xu, H.; Richer, M.J.; Jean, F.: Development of a red-shifted fluorescence-based assay for SARScoronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata. Biol. Chem., 387, 1063-1074 (2006)
Chen, L.; Li, J.; Luo, C.; Liu, H.; Xu, W.; Chen, G.; Liew, O.W.; Zhu, W.; Puah, C.M.; Shen, X.; Jiang, H.: Binding interaction of quercetin-3-β -galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure-activity relationship studies reveal salient pharmacophore features. Bioorg. Med. Chem., 14, 8295-8306 (2006)
Niu, C.; Yin, J.; Zhang, J.; Vederas, J.C.; James, M.N.: Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro. Bioorg. Med. Chem., 16, 293-302 (2008)
Ghosh, A.K.; Xi, K.; Grum-Tokars, V.; Xu, X.; Ratia, K.; Fu, W.; Houser, K.V.; Baker, S.C.; Johnson, M.E.; Mesecar, A.D.: Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. Bioorg. Med. Chem. Lett., 17, 5876-5880 (2007)
Chang, H.; Chou, C.; Chang, G.: Reversible unfolding of the severe acute respiratory syndrome coronavirus main protease in guanidinium chloride. Biophys. J., 92, 1374-1383 (2007)
Wu, C.; King, K.; Kuo, C.; Fang, J.; Wu, Y.; Ho, M.; Liao, C.; Shie, J.; Liang, P.; Wong, C.: Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease. Chem. Biol., 13, 261-268 (2006)
Shao, Y.; Yang, W.; Peng, H.; Hsu, M.; Tsai, K.; Kuo, T.; Wang, A.H.; Liang, P.; Lin, C.; Yang, A.; Wong, C.: Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors. Chembiochem, 8, 1654-1657 (2007)
Lai, L.; Han, X.; Chen, H.; Wei, P.; Huang, C.; Liu, S.; Fan, K.; Zhou, L.; Liu, Z.; Pei, J.; Liu, Y.: Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase. Curr. Pharm. Des., 12, 4555-4564 (2006)
Liang, P.: Characterization and inhibition of SARS-coronavirus main protease. Curr. Top. Med. Chem., 6, 361-376 (2006)
Shi, J.; Song, J.: The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain. FEBS J., 273, 1035-1045 (2006)
Chen, H.; Wei, P.; Huang, C.; Tan, L.; Liu, Y.; Lai, L.: Only one protomer is active in the dimer of SARS 3C-like proteinase. J. Biol. Chem., 281, 13894-13898 (2006)
Chen, S.; Hu, T.; Zhang, J.; Chen, J.; Chen, K.; Ding, J.; Jiang, H.; Shen, X.: Mutation of Gly-11 on the dimer interface results in the complete crystallographic dimer dissociation of severe acute respiratory syndrome coronavirus 3C-like protease. Crystal structure with molecular dynamics simulations. J. Biol. Chem., 283, 554-564 (2008)
Yang, S.; Chen, S.; Hsu, M.; Wu, J.; Tseng, C.K.; Liu, Y.; Chen, H.; Kuo, C.; Wu, C.; Chang, L.; Chen, W.; Liao, S.; Chang, T.; Hung, H.; Shr, H.; Liu, C.; Huang, Y.; Chang, L.; Hsu, J.; Peters, C.J.; Wang, A.H.; Hsu, M.: Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. J. Med. Chem., 49, 4971-4980 (2006)
Lu, I.; Mahindroo, N.; Liang, P.; Peng, Y.; Kuo, C.; Tsai, K.; Hsieh, H.; Chao, Y.; Wu, S.: Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease. J. Med. Chem., 49, 5154-5161 (2006)
Wen, C.; Kuo, Y.; Jan, J.; Liang, P.; Wang, S.; Liu, H.; Lee, C.; Chang, S.; Kuo, C.; Lee, S.; Hou, C.; Hsiao, P.; Chien, S.; Shyur, L.; Yang, N.: Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J. Med. Chem., 50, 4087-4095 (2007)
Lee, T.; Cherney, M.M.; Liu, J.; James, K.E.; Powers, J.C.; Eltis, L.D.; James, M.N.: Crystal structures reveal an induced-fit binding of a substrate-like aza-peptide epoxide to SARS coronavirus main peptidase. J. Mol. Biol., 366, 916-932 (2007)
Yin, J.; Niu, C.; Cherney, M.M.; Zhang, J.; Huitema, C.; Eltis, L.D.; Vederas, J.C.; James, M.N.: A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase. J. Mol. Biol., 371, 1060-1074 (2007)
Zheng, K.; Ma, G.; Zhou, J.; Min, Z.; Zhao, W.; Jiang, Y.; Yu, Q.; Feng, J.: Insight into the activity of SARS main protease: molecular dynamics study of dimeric and monomeric form of enzyme. Proteins Struct. Funct. Bioinform., 66, 467-479 (2007)
Lin, P.Y.; Chou, C.Y.; Chang, H.C.; Hsu, W.C.; Chang, G.G.: Correlation between dissociation and catalysis of SARS-CoV main protease. Arch. Biochem. Biophys., 472, 34-42 (2008)
Fan, K.; Wei, P.; Feng, Q.; Chen, S.; Huang, C.; Ma, L.; Lai, B.; Pei, J.; Liu, Y.; Chen, J.; Lai, L.J.: Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. Biol. Chem., 279, 1637-1642 (2004)
Zhang, J.; Huitema, C.; Niu, C.; Yin, J.; James, M.N.; Eltis, L.D.; Vederas, J.C.: Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for severe acute respiratory syndrome (SARS) 3C-like proteinase. Bioorg. Chem., 36, 229-240 (2008)
Mukherjee, P.; Desai, P.; Ross, L.; White, E.L.; Avery, M.A.: Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits. Bioorg. Med. Chem., 16, 4138-4149 (2008)
Shao, Y.M.; Yang, W.B.; Kuo, T.H.; Tsai, K.C.; Lin, C.H.; Yang, A.S.; Liang, P.H.; Wong, C.H.: Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease. Bioorg. Med. Chem., 16, 4652-4660 (2008)
Akaji, K.; Konno, H.; Onozuka, M.; Makino, A.; Saito, H.; Nosaka, K.: Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant. Bioorg. Med. Chem., 16, 9400-9408 (2008)
Ghosh, A.K.; Gong, G.; Grum-Tokars, V.; Mulhearn, D.C.; Baker, S.C.; Coughlin, M.; Prabhakar, B.S.; Sleeman, K.; Johnson, M.E.; Mesecar, A.D.: Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors. Bioorg. Med. Chem. Lett., 18, 5684-5688 (2008)
Phakthanakanok, K.; Ratanakhanokchai, K.; Kyu, K.L.; Sompornpisut, P.; Watts, A.; Pinitglang, S.: A computational analysis of SARS cysteine proteinase-octapeptide substrate interaction: implication for structure and active site binding mechanism. BMC Bioinformatics, 10 Suppl 1, S48 (2009)
Bacha, U.; Barrila, J.; Gabelli, S.B.; Kiso, Y.; Mario Amzel, L.; Freire, E.: Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro). Chem. Biol. Drug Des., 72, 34-49 (2008)
Yang, Q.; Chen, L.; He, X.; Gao, Z.; Shen, X.; Bai, D.: Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors. Chem. Pharm. Bull., 56, 1400-1405 (2008)
Kuo, C.J.; Liu, H.G.; Lo, Y.K.; Seong, C.M.; Lee, K.I.; Jung, Y.S.; Liang, P.H.: Individual and common inhibitors of coronavirus and picornavirus main proteases. FEBS Lett., 583, 549-555 (2009)
Chen, S.; Zhang, J.; Hu, T.; Chen, K.; Jiang, H.; Shen, X.: Residues on the dimer interface of SARS coronavirus 3C-like protease: dimer stability characterization and enzyme catalytic activity analysis. J. Biochem., 143, 525-536 (2008)
Lee, C.C.; Kuo, C.J.; Ko, T.P.; Hsu, M.F.; Tsui, Y.C.; Chang, S.C.; Yang, S.; Chen, S.J.; Chen, H.C.; Hsu, M.C.; Shih, S.R.; Liang, P.H.; Wang, A.H.: Structural basis of inhibition specificities of 3C and 3C-like proteases by zinccoordinating and peptidomimetic Compounds. J. Biol. Chem., 284, 7646-7655 (2009)
Taranto, A.G.; Carvalho, P.; Avery, M.A.: QM/QM studies for Michael reaction in coronavirus main protease (3CL Pro). J. Mol. Graph. Model., 27, 275-285 (2008)
Zhong, N.; Zhang, S.; Zou, P.; Chen, J.; Kang, X.; Li, Z.; Liang, C.; Jin, C.; Xia, B.: Without its N-finger, the main protease of severe acute respiratory syndrome coronavirus can form a novel dimer through its C-terminal domain. J. Virol., 82, 4227-4234 (2008)
Shi, J.; Sivaraman, J.; Song, J.: Mechanism for controlling the dimer-monomer switch and coupling dimerization to catalysis of the severe acute respiratory syndrome coronavirus 3C-like protease. J. Virol., 82, 4620-4629 (2008)
Chu, L.H.; Choy, W.Y.; Tsai, S.N.; Rao, Z.; Ngai, S.M.: Rapid peptide-based screening on the substrate specificity of severe acute respiratory syndrome (SARS) coronavirus 3C-like protease by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Protein Sci., 15, 699-709 (2006)
Zhong, N.; Zhang, S.; Xue, F.; Kang, X.; Zou, P.; Chen, J.; Liang, C.; Rao, Z.; Jin, C.; Lou, Z.; Xia, B.: C-terminal domain of SARS-CoV main protease can form a 3D domain-swapped dimer. Protein Sci., 18, 839-844 (2009)
Regnier, T.; Sarma, D.; Hidaka, K.; Bacha, U.; Freire, E.; Hayashi, Y.; Kiso, Y.: New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors. Bioorg. Med. Chem. Lett., 19, 2722-2727 (2009)
Ryu, Y.B.; Park, S.J.; Kim, Y.M.; Lee, J.Y.; Seo, W.D.; Chang, J.S.; Park, K.H.; Rho, M.C.; Lee, W.S.: SARS-CoV 3CLpro inhibitory effects of quinonemethide triterpenes from Tripterygium regelii. Bioorg. Med. Chem. Lett., 20, 1873-1876 (2010)
Ramajayam, R.; Tan, K.P.; Liu, H.G.; Liang, P.H.: Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease. Bioorg. Med. Chem. Lett., 20, 3569-3572 (2010)
Cheng, S.C.; Chang, G.G.; Chou, C.Y.: Mutation of Glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease. Biophys. J., 98, 1327-1336 (2010)
Luo, W.; Su, X.; Gong, S.; Qin, Y.; Liu, W.; Li, J.; Yu, H.; Xu, Q.: Anti-SARS coronavirus 3C-like protease effects of Rheum palmatum L. extracts. Biosci. Trends, 3, 124-126 (2009)
Kuo, C.J.; Shih, Y.P.; Kan, D.; Liang, P.H.: Engineering a novel endopeptidase based on SARS 3CL(pro). Biotechniques, 47, 1029-1032 (2009)
Li, C.; Qi, Y.; Teng, X.; Yang, Z.; Wei, P.; Zhang, C.; Tan, L.; Zhou, L.; Liu, Y.; Lai, L.: Maturation mechanism of severe acute respiratory syndrome (SARS) coronavirus 3C-like proteinase. J. Biol. Chem., 285, 28134-28140 (2010)
Hu, T.; Zhang, Y.; Li, L.; Wang, K.; Chen, S.; Chen, J.; Ding, J.; Jiang, H.; Shen, X.: Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure. Virology, 388, 324-334 (2009)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schomburg, D., Schomburg, I. (2013). SARS coronavirus main proteinase 3.4.22.69. In: Schomburg, D., Schomburg, I. (eds) Class 3.4–6 Hydrolases, Lyases, Isomerases, Ligases. Springer Handbook of Enzymes, vol 10. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-36260-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-36260-6_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-36259-0
Online ISBN: 978-3-642-36260-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)